ValuEngine lowered shares of Spark Therapeutics, Inc. (NASDAQ:ONCE) from a hold rating to a sell rating in a research note released on Tuesday morning.

Several other research firms have also recently weighed in on ONCE. Goldman Sachs Group, Inc. (The) reissued a buy rating and issued a $111.00 price target on shares of Spark Therapeutics in a research note on Friday, October 6th. Cowen and Company reissued a buy rating and issued a $95.00 price target on shares of Spark Therapeutics in a research note on Tuesday, October 10th. BMO Capital Markets set a $89.00 price target on shares of Spark Therapeutics and gave the company a buy rating in a research note on Tuesday, October 10th. Raymond James Financial, Inc. assumed coverage on shares of Spark Therapeutics in a research note on Thursday, October 12th. They issued an outperform rating and a $96.00 price target for the company. Finally, Chardan Capital reissued a buy rating and issued a $100.00 price target on shares of Spark Therapeutics in a research note on Friday, October 13th. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and eighteen have assigned a buy rating to the stock. The stock has a consensus rating of Buy and a consensus price target of $90.36.

Spark Therapeutics (ONCE) traded down $4.40 during trading on Tuesday, hitting $68.25. 961,900 shares of the stock traded hands, compared to its average volume of 398,382. Spark Therapeutics has a twelve month low of $47.03 and a twelve month high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last posted its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share for the quarter, missing the consensus estimate of ($1.79) by ($0.11). Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The firm had revenue of $1.90 million during the quarter, compared to analysts’ expectations of $1.40 million. During the same period last year, the company earned ($1.07) EPS. The business’s quarterly revenue was up 45.8% on a year-over-year basis. sell-side analysts forecast that Spark Therapeutics will post -7.62 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Spark Therapeutics, Inc. (ONCE) Downgraded by ValuEngine to Sell” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/11/15/spark-therapeutics-inc-once-downgraded-by-valuengine-to-sell.html.

In other Spark Therapeutics news, CEO Jeffrey D. Marrazzo sold 20,000 shares of the stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $71.54, for a total transaction of $1,430,800.00. Following the sale, the chief executive officer now directly owns 250,000 shares in the company, valued at approximately $17,885,000. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Barge Joseph La sold 3,309 shares of the stock in a transaction that occurred on Thursday, November 9th. The stock was sold at an average price of $71.31, for a total transaction of $235,964.79. Following the sale, the insider now owns 8,146 shares in the company, valued at $580,891.26. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,099,659 shares of company stock worth $92,457,658. 7.30% of the stock is owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. raised its holdings in shares of Spark Therapeutics by 11.6% in the 2nd quarter. BlackRock Inc. now owns 2,053,734 shares of the biotechnology company’s stock valued at $122,689,000 after purchasing an additional 213,520 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Spark Therapeutics by 5.3% in the 2nd quarter. Vanguard Group Inc. now owns 1,924,463 shares of the biotechnology company’s stock valued at $114,968,000 after purchasing an additional 96,803 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Spark Therapeutics by 15.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock valued at $164,986,000 after purchasing an additional 241,016 shares in the last quarter. Janus Henderson Group PLC raised its holdings in shares of Spark Therapeutics by 46.4% in the 3rd quarter. Janus Henderson Group PLC now owns 756,088 shares of the biotechnology company’s stock valued at $67,413,000 after purchasing an additional 239,723 shares in the last quarter. Finally, Orbimed Advisors LLC acquired a new stake in shares of Spark Therapeutics in the 3rd quarter valued at $38,340,000. Institutional investors own 77.94% of the company’s stock.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.